Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced the publication of the primary analysis of KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS) in the Journal of the American Medical Association (JAMA) Neurology. These published data were presented in a late-breaking oral presentation at the American Academy of Neurology (AAN) Annual Meeting in April 2026. Kyverna also recently shared its one-year durability data from the KYSA-8 trial at MS Toronto, the joint ACTRIMS-ECTRIMS meeting.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.